New hope for cancer patients when immunotherapy fails?
NCT ID NCT03881488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients whose tumors no longer respond to standard PD-1/PD-L1 inhibitors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CTX-471 (an experimental antibody) and pembrolizumab (Keytruda)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced cancers that no longer respond to standard immunotherapy.
- What could go wrong
- This is an early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University School of Medicine
Durham, North Carolina, 27705, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida, 34952, United States
-
Institute for Translational Oncology Research (ITOR)
Greenville, South Carolina, 29605, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mt Sinai
New York, New York, 10029, United States
-
Ocala Oncology Center
Ocala, Florida, 34474, United States
-
Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can new drug cocktails reawaken the immune system against melanoma?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?